Charlie Scott

机构：Bayer (United States), Bayer (Germany) · ORCID：0000-0002-2816-4889

发表论文 60 篇 · 总被引 1125 次 · h-index 15

代表论文

• Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (2025 · New England Journal of Medicine · 被引 257)
• COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics (2025 · Nephrology Dialysis Transplantation · 被引 25)
• Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis (2025 · Kidney International · 被引 16)
• Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) (2025 · Diabetes Care · 被引 13)
• Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study (2025 · Clinical Kidney Journal · 被引 8)
• Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both (2025 · Journal of the American College of Cardiology · 被引 6)